As pharmaceutical and biotechnology manufacturers continue to strengthen contamination control strategies in response to evolving regulatory expectations, Pre-Use Post-Sterilization Integrity Testing (PUPSIT) has become a key element in sterile manufacturing design.
While PUPSIT enhances sterility assurance by verifying the integrity of sterilizing-grade filters before product filtration, its implementation raises an important challenge:
How can manufacturers ensure full regulatory compliance without introducing unnecessary complexity or reducing operational efficiency?
The answer lies in intelligent system design, integrated engineering, and a contamination control strategy built “by design” rather than “by end-product testing.” Successfully implementing PUPSIT requires a comprehensive assessment of existing systems, process risks, validation impacts, operational constraints, and long-term manufacturing objectives.
This is where experienced engineering partners can provide significant value.
Sterile Manufacturing in the Context of EU GMP Annex 1
A major driver behind the increased focus on PUPSIT is the revised EU GMP Annex 1 guideline for the manufacture of sterile medicinal products.
With its final revision effective from 2023, Annex 1 represents one of the most significant updates to sterile manufacturing regulations in decades. It reflects a global shift toward harmonized expectations, with contributions from international bodies including the FDA, WHO, and ISPE. As a result, Annex 1 is widely regarded as a de facto global benchmark for sterile manufacturing.
At the heart of Annex 1 is a fundamental principle: Contamination must be prevented by design, not detected by testing alone.
This marks a shift toward a risk-based, knowledge-driven approach aligned with Quality by Design (QbD), where sterility assurance is embedded into process and facility design from the earliest stages.
Contamination Control Strategy: The Core of Annex 1
A central requirement of Annex 1 is the implementation of a robust Contamination Control Strategy (CCS). The CCS is a comprehensive, site-specific framework that defines how contamination risks are identified, controlled, and continuously mitigated across the entire facility and process lifecycle.
It integrates Facility and process design; Equipment and utilities; Personnel and operational practices; Validation and documentation systems.
Within this structure, filtration integrity verification, and specifically PUPSIT, plays an increasingly important role as part of a holistic contamination control approach.
Whether the solution involves modifications to existing filling lines, stainless-steel filtration assemblies, or single-use technologies, the objective remains the same: achieving robust sterility assurance while minimizing complexity, downtime, and unnecessary investment.
Drawing on decades of expertise in aseptic processing and pharmaceutical facility design, MEPEQ and ZETA help manufacturers identify the most suitable path toward Annex 1 readiness. Through feasibility studies, risk assessments, process evaluations, and implementation planning, manufacturers gain a clear understanding of available options and the operational implications of each approach.
Implementing PUPSIT in Existing Manufacturing Facilities
PUPSIT (Pre-Use Post-Sterilization Integrity Testing) is the process of verifying the integrity of a sterilizing-grade filter after sterilization but before product filtration.
It ensures that:
• The filter has not been damaged during installation or sterilization
• The sterilizing barrier remains fully functional before product exposure
• A documented verification step supports sterility assurance
Common test methods include bubble point, diffusion, and pressure hold testing. From a manufacturing perspective, PUPSIT adds a critical layer of confidence but also introduces engineering and operational considerations that must be carefully managed.
For many pharmaceutical and biotechnology manufacturers, the challenge is not designing a new sterile manufacturing facility from scratch. It is adapting existing production lines and validated processes to meet evolving Annex 1 expectations. Adding PUPSIT to an established manufacturing environment can affect equipment layouts, automation systems, validation strategies, production schedules, and operating procedures.
MEPEQ and ZETA carefully evaluate how to introduce additional filtration and integrity testing steps while minimizing downtime, preserving process efficiency, and maintaining product quality.
As a result, the question is no longer whether PUPSIT should be implemented, but how it can be implemented in the most practical, reliable, and cost-effective way.
MEPEQ and ZETA help pharmaceutical manufacturers adopt an integrated design philosophy, where PUPSIT is embedded into the process system architecture rather than added as an afterthought.
This approach ensures:
• Hygienic system design with minimal dead legs
• Secure sterile boundaries during testing
• Reduced operator intervention through automation
• Seamless integration into Contamination Control Strategy (CCS)
• Reliable and repeatable integrity testing performance
Therefore, PUPSIT is no longer treated as an isolated regulatory requirement, but as part of an integrated sterile manufacturing strategy.
PUPSIT should not become a source of operational burden. When approached strategically, it can be integrated into existing manufacturing environments in a way that supports both compliance and performance.
Through a combination of engineering expertise, risk-based decision-making, and deep knowledge of aseptic processing, MEPEQ and ZETA help manufacturers implement PUPSIT solutions that are practical, validated, and aligned with real-world production requirements. Through its regional presence and technical expertise, MEPEQ brings these capabilities closer to manufacturers across the Middle East and surrounding markets, providing local project execution, engineering support, and lifecycle services.
ZETA and MEPEQ’s subject-matter experts have both the technical knowledge in GMP-compliant, biopharmaceutical processing and many years of experience in designing aseptic facilities. They identify and close gaps in achieving Annex 1 regulatory compliance, turning them into robust solutions.
By combining global expertise with local execution, manufacturers benefit from a single point of responsibility, reduced project complexity, and seamless delivery of critical sterile manufacturing solutions.
About ZETA
ZETA is a globally operating end-to-end solution provider specialized in the design, construction, automation, and qualification of customer-specific systems for aseptic production processes. ZETA offers comprehensive solutions and services along the whole pathway of active substance development and manufacturing. In addition, ZETA serves as an EPCM contractor for major pharmaceutical projects, drives digital innovations, and develops comprehensive decarbonization strategies.
About MEPEQ
As the official commercial and technical partner of ZETA in the Middle East, MEPEQ combines regional engineering expertise with world-class pharmaceutical manufacturing solutions. Supported by dedicated local technical teams, manufacturers benefit from a fully integrated approach, from process design and system engineering to end-of-line solutions, delivered through a single point of responsibility for efficient, seamless project execution.
